Abstract The production of peptides as active pharmaceutical ingredients (APIs) by recombinant technologies is emerging interest. A reliable platform, however, still missing due the inherent characteristics such proteolytic sensitivity, aggregation and cytotoxicity. We have developed a new technology named Numaswitch solving present limitations. was successfully employed for diverse small prote...

Purpose. Determine patient-reported reasons for discontinuation with teriparatide. Methods. Patients taking teriparatide in a multicenter, prospective, and observational study were given three questionnaires: baseline, follow-up questionnaire 1 (QF1, 2 to 6 months), and follow-up questionnaire 2 (QF2, 12 months). Discontinuation reported at QF1 and QF2 was defined as "early" and "late," respect...

BACKGROUND Collapse of the femoral head associated with nontraumatic osteonecrosis (NOFH) is one of the most common causes of disability in young adult patients. Excessive bone resorption by osteoclast coincident with the suppression of osteogenesis are believed to be responsible for collapse progression. Alendronate that inhibits bone resorption by inducing osteoclast apoptosis has been tradit...

Osteoporosis is frequent in elderly people, causing bone fractures and lowering their quality of life. The costs incurred by these constitute a problem for public health. Markov chains were used to carry out an incremental cost-utility analysis the four main drugs Spain treat osteoporosis (alendronate, risedronate, denosumab teriparatide). We considered 14 clinical transition states, from start...

We examined the individual and combined effects of teriparatide and anti-RANKL (receptor activator of nuclear factor κB ligand) monoclonal antibody in ovariectomized mice. Three-month-old female C57BL/6 mice were ovariectomized (OVX) or sham operated. Four weeks after OVX, they were assigned to 3 different groups to receive anti-RANKL monoclonal antibody (Ab) alone (5 mg/kg single injection at ...

The prevalence of osteoporosis is likely to rise with the increase in life expectancy of an ageing population. Current first line therapies for the treatment of osteoporosis are predominantly anti-resorptive. Teriparatide is a first in class, anabolic agent with a unique mechanism that results in increased bone formation. Daily subcutaneous injection for 6–24 months was effective in reducing ve...

Currently, treatment with parathyroid hormone (PTH) is the only proven and approved method of increasing bone mass and improving bone architecture. This section reviews some selected aspects of treatment with Teriparatide rhPTH(1-34). Teriparatide stimulates bone formation and remodeling thereby increasing BMD as measured by DXA and improves micro architecture (such as BV/TV, trabecular thickne...

BACKGROUND Improper medication adherence is associated with increased morbidity, healthcare costs, and fracture risk among patients with osteoporosis. The objective of this study was to evaluate the healthcare utilization patterns of Medicare Part D beneficiaries newly initiating teriparatide, and to assess the association of medication adherence and persistence with bone fracture. METHODS Th...

Abstract Background Stress fractures are a common and potentially debilitating overuse injury to bone occur frequently among military recruits athletes. Recovery from lower body stress fracture typically requires several weeks of physical rehabilitation. Teriparatide, recombinant form the bioactive portion parathyroid hormone (1–34 amino acids), is used treat osteoporosis, prevent osteoporotic ...

Antiresorptive agents for osteoporosis are a cornerstone of therapy, but anabolic drugs have recently widened our therapeutic options. By directly stimulating bone formation, anabolic agents reduce fracture incidence by improving bone qualities besides increasing bone mass. In this article, we review the role of anabolic treatment for osteoporosis. The only anabolic agent currently approved in ...